Association of skin necrosis with subcutaneous immunoglobulin therapy

doi:10.1016/j.anai.2014.05.025

Annals of Allergy, Asthma & Immunology

Volume 113, Issue 2, August 2014, Pages 232-233

https://doi.org/10.1016/j.anai.2014.05.025 Get rights and content

Section snippets

Acknowledgment

We thank Dr Richard Wasserman for his insightful revisions and comments and the patients and their families.

References (6)

M.J. Thomas et al.
Rapid subcutaneous immunoglobulin infusions in children
Lancet
(1993)
H.D. Ochs et al.
Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases
J Clin Immunol
(2006)
L. Kobrynski
Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
Biologics
(2012)

There are more references available in the full text version of this article.

Cited by (6)

Subcutaneous abdominal abscesses in a patient with common variable immunodeficiency receiving subcutaneous immunoglobulin therapy
2017, Journal of Allergy and Clinical Immunology: In Practice
Blood, Blood Components, Plasma, and Plasma Products
2015, Side Effects of Drugs Annual
Citation Excerpt :
She had resolution of infection after 9 days of antibiotic treatment. One month after her SCIG treatment she developed a blister at the injection site again, treated with clindamycin, but no development of necrosis of the skin [67A]. The British Committee for Standards in Hematology (BCSH) published a guideline for use of Anti-D immunoglobulin to prevent hemolysis in newborns and fetuses.
This review of the 2013–2014 publications on important side effects of blood, blood components, plasma, and plasma products covers albumin, blood transfusion (erythrocytes, granulocytes, and platelets), blood substitutes (hemoglobin-based oxygen carriers), plasma products (alpha1-antitrypsin, C1 esterase inhibitor concentrate, cryoprecipitate, and fresh frozen plasma), plasma substitutes (dextrans, etherified starches, and gelatin), globulins (intravenous immunoglobulin, subcutaneous immunoglobulin, and Anti-D immunoglobulin), coagulation proteins (factor I, factor II, factor VIIa, factor VIII, factor IX, prothrombin complex concentrate, and von Willebrand factor/factor VIII concentrates), erythropoietin and derivatives, thrombopoietin and receptor agonists, transmission of infectious agents through blood donation, and stem cells.
This chapter includes blood products for which hemovigilance is in force, and allows the reader to stay up to date on newly recognized and published data in the blood product arena. Since blood and plasma products are available through blood donation, prevention of transmitted infections is of extreme importance and is also discussed here.
Recommendations for Management of Noncytotoxic Vesicant Extravasations
2020, Journal of Infusion Nursing
Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
2017, Journal of Clinical Immunology
Persistent Skin Pouches Following Subcutaneous Immunoglobulin Infusions in a Girl with Immunodeficiency, Bullous Skin Lesions and Melanosis Oculi
2017, Journal of Clinical Immunology
Skin Necrosis Following Subcutaneous Immunoglobulin (SCIg)
2017, Journal of Clinical Immunology

: Disclosure: Dr. de la Morena has received grant support from the Jeffrey Modell Foundation. The other authors have nothing to disclose.

View full text

LetterAssociation of skin necrosis with subcutaneous immunoglobulin therapy

Section snippets

Acknowledgment

Lancet

Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases

J Clin Immunol

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases

Biologics

Letter
Association of skin necrosis with subcutaneous immunoglobulin therapy